Publication | Closed Access
Endpoints in oncology clinical trials.
55
Citations
0
References
2018
Year
Health SciencesClinical EndpointsMedicineCancer ManagementClinical EndpointAppropriate EndpointClinical TrialsOutcomes ResearchCancer RegistrationSecondary EndpointsCancer TreatmentOncologyRadiation OncologyCancer ResearchOncology Clinical TrialsGold Standard Endpoint
Oncology trials use diverse endpoints, with overall survival as the gold standard but limited by long follow‑up, large sample needs, and high cost, especially as newer treatments extend survival. The review seeks to determine the most appropriate endpoint for oncology clinical trials. The authors conduct a review of oncology trial endpoints. No additional metadata.
In oncology clinical trials, many different endpoints can be used as primary or secondary endpoints. Advances in cancer treatment have provided longer survival outcomes, particularly in certain types of cancer. Overall survival is accepted as the gold standard endpoint for demonstrating clinical benefit; however, it is associated with some disadvantages such as requirement of long-term follow-up, requirement of higher number of patients, and high cost. Thus, the question "what is the most appropriate endpoint in clinical trials?" comes to mind. The present review discusses the endpoints in oncology clinical trials.